Clinical and Microbiological Characteristics of Patients with Complicated Intra-abdominal Infections in Intensive Care Unit

被引:12
|
作者
Xiong, Yang-mei [1 ]
Rao, Xin [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Intens Care Unit, Wuhan 430071, Peoples R China
基金
中国国家自然科学基金;
关键词
complicated intra-abdominal infection; pathogens; extended spectrum beta-lactamase screen positive isolates; resistance rate; URINARY-TRACT-INFECTIONS; GRAM-NEGATIVE BACILLI; ESCHERICHIA-COLI; SUSCEPTIBILITIES; MANAGEMENT; ADULTS;
D O I
10.1007/s11596-020-2152-x
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In order to investigate the clinical and microbiological characteristics of patients with complicated intra-abdominal infections (cIAIs) in intensive care unit (ICU), the clinical data of 612 cIAIs patients from January 2016 to December 2018 were retrospectively collected. Clinical characteristics, distribution of pathogens and drug resistance were statistically analyzed. It was found that patients with community-acquired intra-abdominal infections (CA-IAIs) made up a majority of cIAIs patients. The positive rate of abdominal drainage fluid culture was 55.56%. Gramnegative bacteria accounted for the majority, the most commonly isolated bacteria of which were Escherichia coli (20.96%), Klebsiella pneumoniae (10.20%) and Pseudomonas aeruginosa (5.57%). The most commonly isolated gram-positive bacteria were Enterococcus (16.88%) and Methicillin-resistant staphylococcus aureus (MRSA, 3.90%). Enterobacter isolates showed high resistance rate to most cephalosporins and low resistance rate to piperacillin/tazobactam and carbapenems. Extended spectrum beta-lactamase (ESBL) screen positive isolates from CA-IAIs patients showed an increasing trend in past three years. Enterococcus and MRSA showed high resistance rate to clindamycin, quinolone, erythromycin and tetracycline, while they showed high sensitivity rate to linezolid, tegacycline, teicoplanin and vancomycin. Our results indicate that isolated bacteria from abdominal drainage fluid show high resistance rates to commonly used antibiotics in ICU patients with cIAIs. The curative effects on diseases should be monitored continuously when antibiotics are used. Meanwhile, we should always keep eyes on drug-resistant bacteria, especially when the treatment efficacy is not good.
引用
收藏
页码:104 / 109
页数:6
相关论文
共 50 条
  • [21] Risk factors for mortality and cost implications of complicated intra-abdominal infections in critically ill patients
    De Pascale, Gennaro
    Carelli, Simone
    Vallecoccia, Maria Sole
    Cutuli, Salvatore Lucio
    Taccheri, Temistocle
    Montini, Luca
    Bello, Giuseppe
    Spanu, Teresa
    Tumbarello, Mario
    Cicchetti, Americo
    Urbina, Irene
    Oradei, Marco
    Marchetti, Marco
    Antonelli, Massimo
    JOURNAL OF CRITICAL CARE, 2019, 50 : 169 - 176
  • [22] Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study
    De Waele, J. J.
    Tellado, J. M.
    Alder, J.
    Reimnitz, P.
    Jensen, M.
    Hampel, B.
    Arvis, P.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2013, 41 (01) : 57 - 64
  • [23] Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited!
    Honore, Patrick M.
    Spapen, Herbert D.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (21)
  • [24] New antimicrobial options for the management of complicated intra-abdominal infections
    Leone, Sebastiano
    Damiani, Giovanni
    Pezone, Ilaria
    Kelly, Molly E.
    Cascella, Marco
    Alfieri, Aniello
    Pace, Maria C.
    Fiore, Marco
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (05) : 819 - 827
  • [25] Outcome of community- versus hospital-acquired intra-abdominal infections in intensive care unit: a retrospective study
    Abaziou, Timothee
    Vardon-Bounes, Fanny
    Conil, Jean-Marie
    Rouget, Antoine
    Ruiz, Stephanie
    Grare, Marion
    Fourcade, Olivier
    Suc, Bertrand
    Leone, Marc
    Minville, Vincent
    Georges, Bernard
    BMC ANESTHESIOLOGY, 2020, 20 (01)
  • [26] Intra-abdominal Infections
    Shirah, Gina R.
    O'Neill, Patrick J.
    SURGICAL CLINICS OF NORTH AMERICA, 2014, 94 (06) : 1319 - +
  • [27] Ceftazidime-Avibactam versus Meropenem for the Treatment of Complicated Intra-Abdominal Infections
    Tan, Che-Kim
    Lai, Chih-Cheng
    Chao, Chien-Ming
    ANTIBIOTICS-BASEL, 2019, 8 (04):
  • [28] Intra-Abdominal Infections
    Mazuski, John E.
    Solomkin, Joseph S.
    SURGICAL CLINICS OF NORTH AMERICA, 2009, 89 (02) : 421 - +
  • [29] Clinical predictors for enterococcal bacteraemia in patients with bacteraemic intra-abdominal infections
    Kang, Cheol-In
    Chung, Doo Ryeon
    Ko, Kwan Soo
    Peck, Kyong Ran
    Song, Jae-Hoon
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 42 (11-12) : 817 - 820
  • [30] Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
    Goodlet, Kellie J.
    Nicolau, David P.
    Nailor, Michael D.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1811 - 1826